Updates - Angle, Densitron, and Avesco

It's been fairly quite on the news front regarding some of my holdings, although in recent weeks   Angle, a specialist medtech company, has released some encouraging news. Firstly they have appointed a specialist regulatory company to manage the process of CE mark and FDA approval for their Parsortix cell separation system and their time targets for both CE and FDA approval appear to be running to schedule. The RNS stated:-

 "Although ANGLE has not yet started to market Parsortix, there has been a stream of potential users expressing interest in the product, particularly in its harvesting capability. These include major hospitals, leading research groups and several commercial companies. Geographically, interest has come from across the UK as well as several international locations including the US, Canada and Australia."

Last week they followed up this news with further positive developments about Parsortix's harvesting capability stating that :-

"the Company has further extended the operational capability of its Parsortix non-invasive cancer diagnostic product by automating its cell harvesting function."

and

"We have seen widespread demand from researchers and clinicians for CTCs to be made available in a test tube after isolation from blood. It is testimony to the versatility of our separation technology that we have been able to introduce and automate this capability in such a short time. The consequent prospects for our Parsortix sales are significant."

Angle will hopefully be launching this product into a multi-billion dollar market eventually, and this harvesting capability appears to be " a major advantage and a key competitive differentiator".

Whilst not allowing myself to get over excited just yet, the news sounds very positive and I await further developments with interest.

On a separate note, I had hoped that Densitron would have released their final results by now. In the previous two years results were released in the first week of May. This is rarely a good sign given that the previous trading update was disappointing.

However, Densitron already has a significant amount of bad news already priced in, and given that it has a strong balance sheet and negligible debt, I continue to hold.

Finally, Avesco will release their interim results in mid June, and whilst this will be a relatively modest year for the group following last year's bumper Olympic contribution, it's worth remembering that Avesco has done extremely well despite the less than favourable worldwide economic conditions in recent years. This is a cyclical company and if the world economy is now beginning to recover more substantially then Avesco will benefit greatly. Underlying growth should continue, the Disney payout will shortly arrive and next year is an even year with the Football World Cup and Winter Olympics to contribute to revenues. Avesco should continue to prosper, and whilst the exact details of the Disney payout are still unknown, the shares are likely to be on a very undemanding rating post any distribution of the cash.